Pupils in Scotland on a unique programme, which aims to improve educational opportunities for young people, have seen a positive impact on their rates of progression to university.

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...